WO2024133302 - CRYSTALLINE FORMS OF A HER2 INHIBITOR
National phase entry:
Publication Number
WO/2024/133302
Publication Date
27.06.2024
International Application No.
PCT/EP2023/086700
International Filing Date
19.12.2023
Title **
[English]
CRYSTALLINE FORMS OF A HER2 INHIBITOR
[French]
FORMES CRISTALLINES D'UN INHIBITEUR DE HER2
Applicants **
BOEHRINGER INGELHEIM INTERNATIONAL GMBH
Inventors
WERTHMANN, Ulrike
GAO, Joe Ju
LI, Huayu
MULDER, Jason Alan
OMAR, Thuraya Mohamed
Priority Data
63/476,733
22.12.2022
US
63/476,715
22.12.2022
US
23156619.1
14.02.2023
EP
23156485.7
14.02.2023
EP
23188330.7
28.07.2023
EP
23383302.9
15.12.2023
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3715 | |
| EPO | Filing, Examination, Granting | 23229 | |
| Japan | Filing, Examination, Granting | 2892 | |
| South Korea | Filing, Examination, Granting | 3743 | |
| USA | Filing, Examination, Granting | 13790 |
Total:
47,369
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present invention relates to crystalline forms of a HER2 inhibitor, processes to prepare the same, pharmaceutical compositions comprising the same and uses thereof, particularly in the treatment and/or prevention of cancer and for the preparation of a solid dispersion of the HER2 inhibitor.[French]
La présente invention concerne des formes cristallines d'un inhibiteur de HER2, des procédés de préparation de celles-ci, des compositions pharmaceutiques les comprenant et leurs utilisations, en particulier dans le traitement et/ou la prévention du cancer et pour la préparation d'une dispersion solide de l'inhibiteur de HER2.